Top Suppliers:I want be here




129-74-8

129-74-8 structure
129-74-8 structure

Name anileridine dihydrochloride
Synonyms 1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)piperazine dihydrochloride
Posdel
1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)diethylenediamine dihydrochloride
1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine dihydrochloride
MFCD00242700
Buclina
1-(4-(tert-Butyl)benzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine dihydrochloride
1-(p-tert-Butylbenzyl)-4-(p-chloro-a-phenylbenzyl)piperazine Dihydrochloride
1-[(4-Chlorophenyl)(phenyl)methyl]-4-[4-(2-methyl-2-propanyl)benzyl]piperazine dihydrochloride
Postafen
BUCLIZINE, DIHYDROCHLORIDE
buclizine hydrochloride
Piperazine, 1- (p-tert-butylbenzyl)-4-(p-chloro-α-phenylbenzyl)-, dihydrochloride
buclizine dihydrochloride
Longifene
Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, hydrochloride (1:2)
1-(p-tert-Butylbenzyl)-4-(p-chloro-α-phenylbenzyl)piperazine dihydrochloride
Piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-α-phenylbenzyl)-, dihydrochloride
Description Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat[1][2][3].
Related Catalog
In Vitro Buclizine (0-100 μM, 72 h) inhibited cancer cell growth by binding to TCTP and induction of cell differentiation[3]. Cell Proliferation Assay[3]. Cell Line: MCF-7 cells[3]. Concentration: 0-100 μM. Incubation Time: 72 h. Result: The IC50 was 19.18 ± 5.32 μM.
In Vivo Buclizine dihydrochloride (≥40 mg/kg) exhibits teratogenic effect[1]. Buclizine dihydrochloride exhibits the t1/2 of ~10 h via oral administration[2]. Animal Model: Eighty-seven mature female rats weighing 240±20 grams[1]. Dosage: 30-200 mg/kg. Administration: From days 10 to 15. Result: Exhibits teratogenic effect dose-dependently when ≥40 mg/kg.
References

[1]. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966 May 1;95(1):109-11.

[2]. Nawab Sher, et al. Simultaneous determination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate, loratadine, meclizine and buclizine in pharmaceutical formulations, human serum and pharmacokinetics application. Analytical methods • March 2014.

[3]. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget . 2016 Mar 29;7(13):16818-39.

Boiling Point 520.1ºC at 760 mmHg
Melting Point 230-240ºC
Molecular Formula C28H35Cl3N2
Molecular Weight 505.950
Flash Point 268.3ºC
Exact Mass 504.186584
PSA 6.48000
LogP 8.02450
Vapour Pressure 6.44E-11mmHg at 25°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TL0280000
CHEMICAL NAME :
Piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-alpha-phenylbenzyl )-, dihydrochloride
CAS REGISTRY NUMBER :
129-74-8
LAST UPDATED :
199701
DATA ITEMS CITED :
4
MOLECULAR FORMULA :
C28-H33-Cl-N2.2Cl-H
MOLECULAR WEIGHT :
506.00
WISWESSER LINE NOTATION :
T6N DNTJ AYR&R DG& D1R DX1&1&1 &GH 2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2100 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - other changes
REFERENCE :
JAPMA8 Journal of the American Pharmaceutical Association, Scientific Edition. (Washington, DC) V.29-49, 1940-60. For publisher information, see JPMSAE. Volume(issue)/page/year: 43,653,1954
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
430 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - other changes
REFERENCE :
JAPMA8 Journal of the American Pharmaceutical Association, Scientific Edition. (Washington, DC) V.29-49, 1940-60. For publisher information, see JPMSAE. Volume(issue)/page/year: 43,653,1954 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
360 mg/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 95,109,1966
Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.